NASDAQ:XCUR
Exicure, Inc. Stock News
$0.474
-0.0012 (-0.253%)
At Close: May 21, 2024
Exicure to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 01'st Sep 2021
CHICAGO, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure to Participate in Upcoming Investor Conferences.
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
02:43pm, Thursday, 05'th Aug 2021
Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid tumors refractory to anti-PD-(L)1 thera
Ever-Glory stock rockets to pace premarket gainers, Exicure leads most-actives list
09:20am, Monday, 02'nd Aug 2021
Shares of Ever-Glory International Group Inc. rocketed 99.1% in active trading early Monday, enough to pace all of the gainers in the premarket session, after the China-based apparel retailer and supp
XCUR Stock Increases Over 55% Pre-Market: Why It Happened
05:43am, Monday, 02'nd Aug 2021
The stock price of Exicure Inc (NASDAQ: XCUR) increased by over 55% pre-market. This is why it happened.
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
01:00am, Monday, 02'nd Aug 2021
PARIS & CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDA
Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)
05:24pm, Thursday, 13'th May 2021
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer
Exicure, Inc. (XCUR) Reports Q4 Loss, Misses Revenue Estimates
10:37am, Thursday, 11'th Mar 2021
Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -50.00% and -95.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University
10:03am, Thursday, 11'th Mar 2021
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Spherical Nucleic Acid technology shows promising results in phase 0 trial in patients with glioblastoma at Northwestern University.
Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress
08:45am, Thursday, 11'th Mar 2021
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure reported fourth quarter and full year financial results for the year ended December 31, 2020 and provided an update on corporate progress.
Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors
08:45am, Tuesday, 09'th Mar 2021
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.
Exicure, Inc. (XCUR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
01:38pm, Tuesday, 02'nd Mar 2021
Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
07:00am, Tuesday, 23'rd Feb 2021
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.
Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference
07:00am, Tuesday, 29'th Dec 2020
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021.
